intravenous treatment with srage  (R&D Systems)

Journal: Breast cancer research and treatment

Article Title: Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation.

doi: 10.1007/s10549-011-1920-5

Figure Lengend Snippet: Fig. 3 Inhibition of RAGE diminishes endothelial cell proliferation and tube formation in response to recombinant psoriasin protein. a HUVECs were infected with psoriasin-expressing adenovirus (Ad- Psoriasin-GFP). After 48 h, HUVEC proliferation was comparable to that of the untreated control cells. b sRAGE significantly prevented HUVEC proliferation in response to psoriasin as compared to cells treated with recombinant psoriasin only. HUVEC proliferation was determined by the MTS assay. c The tube formation of HUVECs was induced by psoriasin (10 lg/ml). HUVECs treated with recombinant psoriasin in combination with sRAGE resulted in reduced tube formation. Control cells are grown with (Pos. Control) or without

Article Snippet: To investigate the effect of RAGE on cell proliferation, HUVECs were treated with an anti-RAGE antibody (20 lg/ml for 3 h) (Millipore, MAB5328) or soluble RAGE (sRAGE) (50 ng/ml for 30 min) (R&D Systems, 1145-RG).

Techniques: Inhibition, Recombinant, Infection, Expressing, Control, MTS Assay

Journal: Breast cancer research and treatment

Article Title: Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation.

doi: 10.1007/s10549-011-1920-5

Figure Lengend Snippet: Fig. 4 Psoriasin induces the proliferation of endothelial cells through interaction with RAGE and increased levels of ROS. a Treatment with VEGF (10 ng/ml for 24 h) and psoriasin (0.15 lg/ml for 24 h) significantly increased the ROS generation in HUVECs. Four experiments were performed in duplicate. b HUVECs treated with sRAGE before the treatment with recombinant psoriasin protein displayed a significantly reduced ROS formation, compared with psoriasin-treated cells. Experiments were performed in duplicate. c HUVECs were infected with Bcl-2-expressing adenovirus (Ad- Bcl2-GFP), prior to the treatment with recombinant psoriasin, which led to a significant reduction in HUVEC proliferation. ROS formation in HUVECs was determined by the NBT assay, and proliferation was determined by the MTS assay. Untreated HUVECs and HUVECs treated with VEGF, sRAGE and Ad-Bcl2-GFP served as controls. Untreated HUVECs were designed as 1, and treated HUVECs, from the same experiment, were normalized to this. The data are expressed as mean ± SD. The P-values (* \ 0.05, ** \ 0.01) were calculated using a one-tailed t-test, ns indicate not statistically significant bars compared with control

Article Snippet: To investigate the effect of RAGE on cell proliferation, HUVECs were treated with an anti-RAGE antibody (20 lg/ml for 3 h) (Millipore, MAB5328) or soluble RAGE (sRAGE) (50 ng/ml for 30 min) (R&D Systems, 1145-RG).

Techniques: Recombinant, Infection, Expressing, MTS Assay, One-tailed Test, Control